与红霉素、阿奇霉素、克拉霉素、罗红霉素及其他抗菌药物相比，泰利霉素（HMR 3647，RU 66647）对罕见厌氧菌的活性。
Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
作者信息
Goldstein E J, Citron D M, Merriam C V, Warren Y, Tyrrell K
机构信息
The R. M. Alden Research Laboratory, Santa Monica-UCLA Medical Center, Santa Monica, California 90404, USA.
出版信息
Antimicrob Agents Chemother. 1999 Nov;43(11):2801-5. doi: 10.1128/AAC.43.11.2801.
Abstract
The comparative activity of telithromycin (HMR 3647) against 419 human anaerobic isolates was determined by the agar dilution method. At concentrations of </=0.5 microgram/ml, telithromycin was active against Actinomyces israelii, Actinomyces odontolyticus, Bacteroides tectum, Bacteroides ureolyticus, Bacteroides gracilis (now Campylobacter gracilis), Porphyromonas spp. (including Porphyromonas gingivalis and Porphyromonas macacae), Prevotella intermedia, Prevotella heparinolytica, and almost all Peptostreptococcus species. Clostridia showed species and strain variability, often with a biphasic pattern. Fusobacterium species, except Fusobacterium russii, were relatively resistant.
摘要
采用琼脂稀释法测定了泰利霉素（HMR 3647）对419株人源厌氧菌的相对活性。在浓度≤0.5微克/毫升时，泰利霉素对以色列放线菌、溶齿放线菌、隐秘拟杆菌、解脲拟杆菌、纤细拟杆菌（现称纤细弯曲菌）、卟啉单胞菌属（包括牙龈卟啉单胞菌和猕猴卟啉单胞菌）、中间普雷沃菌、解肝素普雷沃菌以及几乎所有消化链球菌属菌种均有活性。梭菌属表现出种属和菌株差异，通常呈双相模式。除了拉氏梭杆菌外，梭杆菌属菌种相对耐药。
相似文献
1
Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
Antimicrob Agents Chemother. 1999 Nov;43(11):2801-5. doi: 10.1128/AAC.43.11.2801.
2
Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans.
Antimicrob Agents Chemother. 1998 May;42(5):1127-32. doi: 10.1128/AAC.42.5.1127.
3
Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).
Antimicrob Agents Chemother. 1997 Sep;41(9):2019-22. doi: 10.1128/AAC.41.9.2019.
4
Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes.
Antimicrob Agents Chemother. 1999 Nov;43(11):2726-30. doi: 10.1128/AAC.43.11.2726.
5
In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria.
J Antimicrob Chemother. 2001 Apr;47(4):467-9. doi: 10.1093/jac/47.4.467.
6
Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
Antimicrob Agents Chemother. 1999 Aug;43(8):2027-31. doi: 10.1128/AAC.43.8.2027.
7
Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
Antimicrob Agents Chemother. 2001 Jan;45(1):345-8. doi: 10.1128/AAC.45.1.345-348.2001.
8
In vitro activity of HMR 3647 against anaerobic bacteria.
J Chemother. 1998 Aug;10(4):280-4. doi: 10.1179/joc.1998.10.4.280.
9
Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole.
Antimicrob Agents Chemother. 1997 May;41(5):1037-41. doi: 10.1128/AAC.41.5.1037.
10
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).
Antimicrob Agents Chemother. 1998 Apr;42(4):965-6. doi: 10.1128/AAC.42.4.965.
引用本文的文献
1
[Efficacy of clarithromycin in the adjuvant treatment of chronic periodontitis: a Meta-analysis].
Hua Xi Kou Qiang Yi Xue Za Zhi. 2020 Jun 1;38(3):290-296. doi: 10.7518/hxkq.2020.03.011.
2
Relative effectiveness of azithromycin in killing intracellular Porphyromonas gingivalis.
Clin Exp Dent Res. 2016 Feb 5;2(1):35-43. doi: 10.1002/cre2.17. eCollection 2016 Jun.
3
Azithromycin enhances phagocytic killing of Aggregatibacter actinomycetemcomitans Y4 by human neutrophils.
J Periodontol. 2015 Jan;86(1):155-61. doi: 10.1902/jop.2014.140183.
4
Effect of gingivitis on azithromycin concentrations in gingival crevicular fluid.
J Periodontol. 2012 Sep;83(9):1122-8. doi: 10.1902/jop.2012.110558. Epub 2012 Feb 14.
5
Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration.
J Periodontol. 2011 Nov;82(11):1582-6. doi: 10.1902/jop.2011.110012. Epub 2011 Mar 21.
6
Clarithromycin accumulation by phagocytes and its effect on killing of Aggregatibacter actinomycetemcomitans.
J Periodontol. 2011 Mar;82(3):497-504. doi: 10.1902/jop.2010.100221. Epub 2010 Oct 8.
7
Azithromycin decreases crevicular fluid volume and mediator content.
J Dent Res. 2010 Aug;89(8):831-5. doi: 10.1177/0022034510368650. Epub 2010 Apr 16.
8
Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.
Clin Pharmacokinet. 2009;48(1):23-38. doi: 10.2165/0003088-200948010-00002.
9
Distribution of systemic clarithromycin to gingiva.
J Periodontol. 2008 Sep;79(9):1712-8. doi: 10.1902/jop.2008.080013.
10
Clarithromycin transport by gingival fibroblasts and epithelial cells.
J Dent Res. 2008 Aug;87(8):777-81. doi: 10.1177/154405910808700812.
本文引用的文献
1
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.
J Antimicrob Chemother. 1998 Dec;42(6):703-9. doi: 10.1093/jac/42.6.703.
2
In vitro activities of ketolide HMR 3647, macrolides, and clindamycin against Coryneform bacteria.
Antimicrob Agents Chemother. 1998 Dec;42(12):3290-2. doi: 10.1128/AAC.42.12.3290.
3
In vitro activity of the new ketolide HMR3647 in comparison with those of macrolides and pristinamycins against Enterococcus spp.
Antimicrob Agents Chemother. 1998 Dec;42(12):3279-81. doi: 10.1128/AAC.42.12.3279.
4
In vitro activity of HMR 3647 against anaerobic bacteria.
J Chemother. 1998 Aug;10(4):280-4. doi: 10.1179/joc.1998.10.4.280.
5
Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans.
Antimicrob Agents Chemother. 1998 May;42(5):1127-32. doi: 10.1128/AAC.42.5.1127.
6
Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).
Antimicrob Agents Chemother. 1997 Sep;41(9):2019-22. doi: 10.1128/AAC.41.9.2019.
7
Antimicrobial activity of RU-66647, a new ketolide.
Diagn Microbiol Infect Dis. 1997 Jan-Feb;27(1-2):7-12. doi: 10.1016/s0732-8893(96)00181-2.
8
In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.
Antimicrob Agents Chemother. 1997 Feb;41(2):454-9. doi: 10.1128/AAC.41.2.454.
9
Characterization of saccharolytic Bacteroides and Prevotella isolates from infected dog and cat bite wounds in humans.
J Clin Microbiol. 1997 Feb;35(2):406-11. doi: 10.1128/jcm.35.2.406-411.1997.
10
Frequency of isolation of Porphyromonas species from infected dog and cat bite wounds in humans and their characterization by biochemical tests and arbitrarily primed-polymerase chain reaction fingerprinting.
Clin Infect Dis. 1996 Dec;23 Suppl 1:S78-82. doi: 10.1093/clinids/23.supplement_1.s78.
Zotero 插件